Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

At 1 year after participants’ ICU stay for acute respiratory failure, mean DLCO was about 5% lower in those who had an ICU oxygenation target of 60 vs 90 mm Hg. Cognitive impairment levels among ...

Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...

Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.

During a medical event on Saturday, Cytokinetics (NASDAQ:CYTK) announced primary results from its Phase 3 MAPLE-HCM trial for lead asset aficamten in symptomatic obstructive hypertrophic ...

In a recent study investigating the effects of prostaglandin E1 (PGE1) on reducing inspired oxygen concentration during one-lung ventilation (OLV), several key findings and outcomes were identified.

(RTTNews) - Cytokinetics, Incorporated (CYTK), Tuesday announced positive topline results from Phase 3 MAPLE-HCM study of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy ...

The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's (NASDAQ:CYTK) ...

Bristol Myers Squibb announced the phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...

Bristol Myers Squibb & Co (NYSE:BMY) on Monday announced topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos (mavacamten) for symptomatic New York Heart Association (NYHA) class II-III ...

Bristol-Myers Squibb's Camzyos has been growing fast as a treatment for hypertrophic cardiomyopathy (HCM), but – with competition looming – its plans to broaden its approved indications have suffered ...